Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

ATOS Relative to the S&P 500

ATOS Relative to the Sector

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Atossa Genetics, Inc. (NASD:ATOS) seasonal charts above shows that a Buy Date of December 29 and a Sell Date of March 19 has resulted in a geometric average return of 37.56% above the benchmark rate of the S&P 500 Total Return Index over the past 13 years. This seasonal timeframe has shown positive results compared to the benchmark in 10 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 13 years by an average of 88.32% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.

To download ATOS seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: ATOS